Page 4 - Agonist News Today

Researchers performed a phase II randomized clinical trial (RCT).

Multiple members of The Obesity Society (TOS) unveiled new research about several anti-obesity medications in development at this year's annual meeting of the American Diabetes Association (ADA) held June 23–26.

Orally administered semaglutide shows significant efficacy in reducing HbA1c and body weight in patients with type 2 diabetes compared to other treatments. The study includes a large number of participants from multiple trials.

LYON, France and CAMBRIDGE, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced

Tirzepatide, a drug approved for diabetes and on the fast track for approval as a weight loss therapy, works through a unique ability to activate two different mechanisms the body uses to control insulin secretion and energy balance, Duke Health researchers report.

AGEN2373 is the first CD137 agonist antibody reporting single agent responses with no major toxicity Responses reported in patients with prostate cancer, ampullary carcinoma and metastatic vulvar... | June 5, 2023

Redefining and Executing Dual Agonist Enterohormone Therapies for Obesity Sarah K. Browne, MD Vice President, Clinical Development ... | May 31, 2023

Highlights from early- and late-stage pipeline include -- combination data for cornerstone therapies BRUKINSA and tislelizumab -- early results for OX40 agonist BGB-A445 and BCL-2 inhibitor... | May 25, 2023

New research presented at this year's European Congress on Obesity (ECO2023, Dublin, 17-20 May) shows that the obesity drug semaglutide is effective for weight loss in a multicentre, 1-year-long real-world study.

A new analysis of SURMOUNT-1, the first Phase 3 study of tirzepatide in adults for chronic weight management shows that tirzepatide improves body composition across a range of adult age groups.